-
10/25/24: Low-dose naltrexone in clinical trials
- 2024/10/26
- 再生時間： 24 分
- ポッドキャスト
-
サマリー
あらすじ・解説
This week, co-hosts Betsy Ladyzhets and Miles Griffis talk with podcast producer James Salanga about clinical trials looking at low-dose naltrexone (LDN) as a potential drug for people living with Long COVID and ME. Also in this episode: the latest COVID-19 numbers, and a new survey of around 70,000 people in China looking at Long COVID, reinfections, and more. The transcript for this podcast is available on The Sick Times' website. You can jump to specific sections of the podcast and transcript below. (00:00:00) Intro (00:01:10) COVID-19 trends (00:03:22) Top story — Low-dose naltrexone clinical trials (00:17:40) Research — Long COVID facts and findings in thousands of Chinese survey participants (00:23:07) Outro and credits Still Here is an abridged version of The Sick Times’ newsletter, which publishes weekly. Sign up here. You can also find our podcast on Apple Podcasts, Pocket Casts, Amazon Music, and iHeartRadio. - Mentioned in this episode (in order of appearance): The Sick Times: National COVID-19 trends, October 22CDC wastewater dashboardBiobot wastewater risk reportsWastewaterSCAN dashboardNature: Daily briefing: COVID protections eliminated a strain of flu CDC: Vaccination Trends | Respiratory IllnessesU.S. free COVID tests: COVID-19 TestingThe Sick Times: Clinical trials explore how Low-Dose Naltrexone could help people with Long COVIDThe Lancet: Regional Health — Western Pacific: Long COVID facts and findings: a large-scale online survey in 74,075 Chinese participantsThe Lancet: Regional Health — Western Pacific: Long Covid is a significant health crisis in China too Research Square: Long COVID and associated outcomes following COVID-19 reinfections: Insights from an International Patient-Led Survey Additional audio in this episode: Rude Mechanical Orchestra: Which Side Are You On? (orig. Florence Reece) Pixabay: Thunder and the beginning of rainfall